B
Brent T. McLaurin
Researcher at University of South Carolina
Publications - 44
Citations - 5026
Brent T. McLaurin is an academic researcher from University of South Carolina. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 22, co-authored 37 publications receiving 4562 citations.
Papers
More filters
Journal ArticleDOI
Bivalirudin for Patients with Acute Coronary Syndromes
Gregg W. Stone,Brent T. McLaurin,David A. Cox,Michel E. Bertrand,A. Michael Lincoff,Jeffrey W. Moses,Harvey D. White,Stuart J. Pocock,James H. Ware,Frederick Feit,Antonio Colombo,Philip E. Aylward,Angel Cequier,Harald Darius,Walter Desmet,Ramin Ebrahimi,Martial Hamon,Lars Hvilsted Rasmussen,Hans J. Rupprecht,James W. Hoekstra,Roxana Mehran,E. Magnus Ohman +21 more
TL;DR: In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin.
Journal ArticleDOI
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt,Gregg W. Stone,Kenneth W. Mahaffey,C. Michael Gibson,P. Gabriel Steg,Christian W. Hamm,Matthew J. Price,Sergio Leonardi,Dianne Gallup,Ezio Bramucci,Peter W. Radke,Petr Widimský,František Toušek,Jeffrey Tauth,Douglas Spriggs,Brent T. McLaurin,Dominick J. Angiolillo,Philippe Généreux,Tiepu Liu,Jayne Prats,Meredith Todd,Simona Skerjanec,Harvey D. White,Robert A. Harrington +23 more
TL;DR: Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.
Journal ArticleDOI
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Gregg W. Stone,Harvey D. White,E. Magnus Ohman,Michel E. Bertrand,A. Michael Lincoff,Brent T. McLaurin,David A. Cox,Stuart J. Pocock,James H. Ware,Frederick Feit,Antonio Colombo,Steven V. Manoukian,Alexandra J. Lansky,Roxana Mehran,Jeffrey W. Moses +14 more
TL;DR: Anticoagulation with bivalirudin alone suppresses adverse ischaemic events to a similar extent as does heparin plus glycoprotein IIb/IIIa inhibitors, while significantly lowering the risk of major haemorrhagic complications.
Journal ArticleDOI
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
Michael Böhm,Kazuomi Kario,David E. Kandzari,Felix Mahfoud,Felix Mahfoud,Michael A. Weber,Roland E. Schmieder,Konstantinos Tsioufis,Stuart J. Pocock,Dimitris Konstantinidis,James W. Choi,Cara East,David P. Lee,Adrian Ma,Sebastian Ewen,Debbie L. Cohen,Robert L. Wilensky,Chandan Devireddy,Janice P. Lea,Axel Schmid,Joachim Weil,Tolga Agdirlioglu,Denise Reedus,Brian K. Jefferson,David Reyes,Richard D'Souza,Andrew S.P. Sharp,Andrew S.P. Sharp,Faisal Sharif,Martin Fahy,Vanessa DeBruin,Sidney Cohen,Sandeep Brar,Raymond R. Townsend,Ertan Akarca,Suhail Allaqaband,Eirini Andrikou,Jiro Aoki,Ahran D. Arnold,Herbert D. Aronow,Masahiko Asami,William Bachinsky,John H. Barton,Kyle Bass,Bryan Batson,Christopher Bell,Barry Bertolet,Yvonne Bewarder,Karl Bihlmaier,Christian Binner,Jason Bloom,Benjamin Blossom,Somjot S Brar,Angela L. Brown,Robert E. Burke,Martin N. Burke,Michael Butler,William J. Calhoun,James Campbell,Steve Carroll,Neil Chapman,Craig Chasen,Shi Chi Cheng,Beth Chia,Nishit Choksi,Jordana B. Cohen,Niall Connolly,Johanna Contreras,Ronan Cusack,George Dangas,Shukri David,Justin E. Davies,Juliane Dederer,Matthew G. Denker,Udo Desch,Matthaios Didangelos,Thomas Dienemann,Kyriakos Dimitriadis,Jean François Dorval,John Estess,Sarah Fan,Karl Fengler,Lee Ferguson,Marat Fudim,Valentin Fuster,Fidel Garcia,Santiago Garcia,Alex Garton,Carl Gessler,Magdi Ghali,Bharat Gummadi,Amit Gupta,A.M. Gutiérrez,Peggy Hardesty,Phillip Hartung,Walter H. Haught,Yonghong Haun,Sara Hays,Wolfgang Helmreich,Douglas Hill,Ingrid Hopper,Yu Horiuchi,Satoshi Hoshide,James P. Howard,Wanda Ikeda,Fued Jan,Rajiv Jauhar,Desmond Jay,James R. Johnson,Thomas Johnston,Schuyler Jones,Susanne Jung,Theodoros Kalos,Mihar Kanitkar,Dennis Kannenkeril,Alexandros Kasiakogias,Samer Kazziha,Daniel Keene,Jayant Khitha,Hosei Kikushima,Taisei Kobayashi,Kota Komiyama,Takahiro Komori,John Kotter,Antonios Kouparanis,Joshua Krasnow,Saarraangan Kulenthiran,Sarwan Kumar,Philippe L. L’Allier,Phillip Laney,Lucas Lauder,Marc A. Lavoie,Matthias Lerche,Elena Linesky,Nelson Little,Carl Lomboy,Jelena Lucic,Philipp Lurz,Shannon Lynch,Prakash Mansukhani,Katie McDuffie,Brian McGrath,Brent T. McLaurin,Ashley Meade,Perwaiz Meraj,Dominic Millenaar,Naing Moore,Fumiko Mori,Phillip Munch,James R. Murphy,Jennifer M. Murray,Aravinda Nanjundappa,Kai Ninomiya,Yusuke Oba,Tim O'Connor,Yukiyo Ogata,Yukako Ogoyama,Rachel Onsrud,Christian Ott,Bimal Padaliya,Neha J. Pagidipati,Manesh R. Patel,Kiritkumar Patel,Emanouela Petteinidou,Wendy Porr,Anjani Rao,Rabia Razi,Christopher Regan,Michael Remetz,David Rizik,Monique Robison,Karl Philipp Rommel,Liesbeth Rosseel,Marcos Rothstein,Randolph Rough,Jose M. Saavedra,Souhell Saba,Robert S. Schwartz,Shaun Selcer,Sayan Sen,Jacqueline Sennott,Ramin Shadman,Samit Shah,Douglas Shemin,Hayato Shimizu,Masahisa Shimpo,Mehdi H. Shishehbor,Matthew J. Shun-Shin,Francisco Sierra,Jasvindar Singh,Avneet Singh,Yassir Sirajeldin,Nedaa Skeik,George Soliman,Sarah Statton,Julia Stehli,Susan Steigerwalt,Kristina Striepe,Jason Stuck,Markus Suppan,Laura P. Svetkey,Ganpat Takker,Kengo Tanabe,Tetsu Tanaka,Daijiro Tomii,Sabino Torre,Jay H. Traverse,Crystal C. Tyson,Alejandro Arias Vasquez,Enrique Velasquez,Sreekanth Vemulapalli,Hirotaka Waki,Tony Walton,Yale Wang,Thomas Weber,Bryan Wells,Robert Wilkins,Thomas C. Wright,Kazuyuki Yahagi,Alan C. Yeung,Ray Zadegan,Thomas Zeller,Khaled M. Ziada,Antonios Ziakas,David A. Zidar +224 more
TL;DR: The SPYRAL HTN-OFF MED (SPYRAL Pivotal) trial showed the superiority of catheter-based renal denervation compared with a sham procedure to safely lower blood pressure in the absence of antihypertensive medications.
Journal ArticleDOI
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
Gregg W. Stone,Michel E. Bertrand,Jeffrey W. Moses,E. Magnus Ohman,A. Michael Lincoff,James H. Ware,Stuart J. Pocock,Brent T. McLaurin,David A. Cox,M. Zubair Jafar,Harish Chandna,Franz Hartmann,Franz Leisch,Ruth H. Strasser,Martin Desaga,Thomas Stuckey,Richard B. Zelman,Ira H. Lieber,David J. Cohen,Roxana Mehran,Harvey D. White,Acuity Trial Investigators +21 more
TL;DR: In this article, the optimal strategy for the use of Gp IIb/IIIa inhibitors in patients with moderate and high-risk acute coronary syndromes undergoing an early, invasive treatment strategy was determined.